A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

Alfred H.J. Kim; Jeffrey A. Sparks; Jean W. Liew; Michael S. Putman; Francis Berenbaum; Alí Duarte-García; Elizabeth R. Graef; Peter Korsten; Sebastian E. Sattui; Emily Sirotich; Manuel F. Ugarte-Gil; Kate Webb; Rebecca Grainger

doi:10.7326/M20-1223

A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

Alfred H.J. Kim, Jeffrey A. Sparks, Jean W. Liew, Michael S. Putman, Francis Berenbaum, Alí Duarte-García, Elizabeth R. Graef, Peter Korsten, Sebastian E. Sattui, Emily Sirotich, Manuel F. Ugarte-Gil, Kate Webb, Rebecca Grainger

Medicina humana

Producción científica: Contribución a una revista › Comentario/Debate

165 Citas (Scopus)

Idioma original	Inglés
Páginas (desde-hasta)	819-821
Número de páginas	3
Publicación	Annals of internal medicine
Volumen	172
N.º	12
DOI	https://doi.org/10.7326/M20-1223
Estado	Publicada - 16 jun. 2020

Acceder al documento

10.7326/M20-1223

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Kim, A. H. J., Sparks, J. A., Liew, J. W., Putman, M. S., Berenbaum, F., Duarte-García, A., Graef, E. R., Korsten, P., Sattui, S. E., Sirotich, E., Ugarte-Gil, M. F., Webb, K., & Grainger, R. (2020). A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Annals of internal medicine, 172(12), 819-821. https://doi.org/10.7326/M20-1223

@article{b4c9731e23cc4bf29b3141fa76c57a3c,

title = "A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19",

author = "Kim, {Alfred H.J.} and Sparks, {Jeffrey A.} and Liew, {Jean W.} and Putman, {Michael S.} and Francis Berenbaum and Al{\'i} Duarte-Garc{\'i}a and Graef, {Elizabeth R.} and Peter Korsten and Sattui, {Sebastian E.} and Emily Sirotich and Ugarte-Gil, {Manuel F.} and Kate Webb and Rebecca Grainger",

note = "Funding Information: Disclosures: Dr. Kim reports personal fees from Exagen Diagnostics and GlaxoSmithKline and grants from the National Institutes of Health and the Rheumatology Research Foundation outside the submitted work. Dr. Sparks reports grants from the National Institute of Allergy and Infectious Diseases Autoimmune Centers of Excellence, National Institutes of Health, during the conduct of the study and personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum outside the submitted work. Dr. Berenbaum reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, No-vartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica, and 4P Pharma outside the submitted work. Dr. Korsten reports personal fees from GlaxoSmith-Kline, Sanofi-Aventis, Pfizer, AbbVie, Novartis Pharma, Lilly, and Bristol-Myers Squibb outside the submitted work. Dr. Sat-tui reports funding from a Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR057319). Dr. Ugarte-Gil reports grants from Pfizer and Janssen outside the submitted work. Dr. Grainger reports nonfinancial support from Pfizer Australia and Janssen Australia and personal fees from Pfizer Australia, Cornerstones, Janssen New Zealand, and Novartis outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www .acponline.org/authors/icmje/ConflictOfInterestForms.do?ms Num=M20-1223.",

year = "2020",

month = jun,

day = "16",

doi = "10.7326/M20-1223",

language = "Ingl{\'e}s",

volume = "172",

pages = "819--821",

journal = "Annals of internal medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "12",

}

Kim, AHJ, Sparks, JA, Liew, JW, Putman, MS, Berenbaum, F, Duarte-García, A, Graef, ER, Korsten, P, Sattui, SE, Sirotich, E, Ugarte-Gil, MF, Webb, K & Grainger, R 2020, 'A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19', Annals of internal medicine, vol. 172, n.º 12, pp. 819-821. https://doi.org/10.7326/M20-1223

TY - JOUR

T1 - A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

AU - Kim, Alfred H.J.

AU - Sparks, Jeffrey A.

AU - Liew, Jean W.

AU - Putman, Michael S.

AU - Berenbaum, Francis

AU - Duarte-García, Alí

AU - Graef, Elizabeth R.

AU - Korsten, Peter

AU - Sattui, Sebastian E.

AU - Sirotich, Emily

AU - Ugarte-Gil, Manuel F.

AU - Webb, Kate

AU - Grainger, Rebecca

N1 - Funding Information: Disclosures: Dr. Kim reports personal fees from Exagen Diagnostics and GlaxoSmithKline and grants from the National Institutes of Health and the Rheumatology Research Foundation outside the submitted work. Dr. Sparks reports grants from the National Institute of Allergy and Infectious Diseases Autoimmune Centers of Excellence, National Institutes of Health, during the conduct of the study and personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum outside the submitted work. Dr. Berenbaum reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, No-vartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica, and 4P Pharma outside the submitted work. Dr. Korsten reports personal fees from GlaxoSmith-Kline, Sanofi-Aventis, Pfizer, AbbVie, Novartis Pharma, Lilly, and Bristol-Myers Squibb outside the submitted work. Dr. Sat-tui reports funding from a Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR057319). Dr. Ugarte-Gil reports grants from Pfizer and Janssen outside the submitted work. Dr. Grainger reports nonfinancial support from Pfizer Australia and Janssen Australia and personal fees from Pfizer Australia, Cornerstones, Janssen New Zealand, and Novartis outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www .acponline.org/authors/icmje/ConflictOfInterestForms.do?ms Num=M20-1223.

PY - 2020/6/16

Y1 - 2020/6/16

UR - http://www.scopus.com/inward/record.url?scp=85083710801&partnerID=8YFLogxK

U2 - 10.7326/M20-1223

DO - 10.7326/M20-1223

M3 - Comentario/Debate

C2 - 32227189

AN - SCOPUS:85083710801

SN - 0003-4819

VL - 172

SP - 819

EP - 821

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 12

ER -